MorphoSys AG (ETR:MOR) has been given a €90.00 ($107.14) price target by analysts at Deutsche Bank AG in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock.

Several other brokerages also recently issued reports on MOR. Independent Research GmbH set a €77.00 ($91.67) price objective on MorphoSys AG and gave the stock a “buy” rating in a research report on Monday, July 24th. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price objective on MorphoSys AG and gave the stock a “neutral” rating in a research report on Monday, July 24th. J P Morgan Chase & Co restated a “neutral” rating on shares of MorphoSys AG in a research report on Monday, July 17th. Commerzbank Ag set a €76.00 ($90.48) price objective on MorphoSys AG and gave the stock a “buy” rating in a research report on Friday, July 14th. Finally, Berenberg Bank set a €68.00 ($80.95) price objective on MorphoSys AG and gave the stock a “buy” rating in a research report on Friday, July 14th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of €70.38 ($83.78).

MorphoSys AG (MOR) opened at 65.25 on Thursday. The firm’s market cap is €1.89 billion. The firm’s 50 day moving average price is €60.15 and its 200-day moving average price is €59.03. MorphoSys AG has a one year low of €35.72 and a one year high of €70.90.

ILLEGAL ACTIVITY NOTICE: “MorphoSys AG (MOR) Given a €90.00 Price Target by Deutsche Bank AG Analysts” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/09/morphosys-ag-mor-given-a-90-00-price-target-by-deutsche-bank-ag-analysts.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.